stockportfolio.pro
uniQure N.V. (QURE)
Healthcare · Biotechnology · NasdaqGS
uniQure N.V. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.10M | $13.11M | $11.28M | $7.28M | $37.51M | $524.00M | $106.48M | $15.84M | $27.12M | $16.10M |
| Gross profit | $23.75M | $12.29M | $10.08M | $5.63M | $34.62M | $499.03M | $103.14M | $2.21M | $8.79M | $14.41M |
| Net income | $-73.37M | $-79.26M | $-83.30M | $-124.20M | $-125.02M | $329.60M | $-126.79M | $-308.48M | $-239.56M | $-198.97M |
| Net margin | -292.3% | -604.7% | -738.2% | -1705.8% | -333.3% | 62.9% | -119.1% | -1947.1% | -883.4% | -1236.0% |
Source: uniQure N.V. SEC filings (10-K). 12 years of history available in the interactive view.
Explore 12 years of uniQure N.V. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track QURE in your portfolio →
uniQure N.V. financial history by metric
About uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
uniQure N.V. — frequently asked questions
What is uniQure N.V.'s revenue?
uniQure N.V. (QURE) reported revenue of $16.10M for fiscal year 2025, down 40.6% from the prior year, according to its SEC filings.
Is uniQure N.V. profitable?
No — QURE reported a net loss of $-198.97M in fiscal 2025.
What is QURE's P/E ratio?
uniQure N.V. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is uniQure N.V. growing?
QURE's revenue grew at roughly -15.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does uniQure N.V. have?
As of fiscal year 2025, QURE carried roughly $49.70M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is uniQure N.V.'s gross margin?
QURE's gross margin was 89.5% in fiscal 2025 — gross profit of $14.41M on revenue of $16.10M.
What is uniQure N.V.'s market cap?
uniQure N.V. (QURE) has a market capitalization of about $1.72B, based on the latest data in our nightly-refreshed cache.
When does uniQure N.V.'s fiscal year end?
QURE's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from uniQure N.V.'s official SEC filings (10-K and 10-Q), covering 12 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.